Finance

Questcor announces net product sales up in 2006 third quarter

Published in Medical Letter on the CDC and FDA, December 10th, 2006

Questcor Pharmaceuticals, Inc. (QSC) reported its financial results for the third quarter with total net product sales for the third quarter of 2006 of $4.0 million, up 22% from $3.3 million in the second quarter of 2006.

Net loss applicable to common shareholders totaled $1.5 million, or $0.03 per share, for the third quarter of 2006, compared to net loss applicable to common shareholders of $2.2 million, or $0.04 per share, for the second quarter of 2006.

The U.S. Food and Drug Administration (FDA) accepted for review Questcor's supplemental new drug application (sNDA) seeking approval for Acthar for the treatment of infantile spasms. Questcor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry